Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023–2025 - Takeaways - MDSpire

Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023–2025

  • By

  • Kamel-Dine Djaliri

  • Adolphe Adjanohoun

  • Pamphile Aguessy

  • Victorien Dougnon

  • Haziz Sina

  • Lamine Baba-Moussa

  • June 4, 2026

  • 0 min

Share

  • 1

    The study assessed residual risks of HIV, HBV, and HCV transmission via blood transfusion in Borgou, Benin, from 2023 to 2025.

  • 2

    A total of 11,113 repeat donors were analyzed, revealing a male predominance and a majority aged 18–30 years.

  • 3

    Incidence rates per 100,000 donor-years were 5.98 for HIV, 350.28 for HBV, and 77.84 for HCV, with significant associations for HBV and HCV by age.

  • 4

    Estimated residual risks were 1 in 277,000 donations for HIV, 1 in 1,862 for HBV, and 1 in 7,070 for HCV, indicating higher risks than in high-income countries.

  • 5

    The findings emphasize the need for improved donor selection, health education, and advanced screening technologies to enhance blood safety in resource-limited settings.

Original Source(s)

Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023–2025

  • by Kamel-Dine Djaliri, Adolphe Adjanohoun, Pamphile Aguessy, Victorien Dougnon, Haziz Sina, Lamine Baba-Moussa

  • June 4, 2026

Related Content

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Hepatitis C Virus Testing in Perinatally Exposed Children

At the Hart of Pathology

Sitting Down With... John Hart, Professor and Vice Chair of Anatomic Pathology at the University of Chicago Medicine